Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2013 1
2014 1
2015 1
2016 3
2017 4
2018 1
2019 1
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

11 results
Results by year
Filters applied: . Clear all
Page 1
Natalizumab in Multiple Sclerosis: Long-Term Management.
Clerico M, Artusi CA, Liberto AD, Rolla S, Bardina V, Barbero P, Mercanti SF, Durelli L. Clerico M, et al. Among authors: bardina v. Int J Mol Sci. 2017 Apr 29;18(5):940. doi: 10.3390/ijms18050940. Int J Mol Sci. 2017. PMID: 28468254 Free PMC article. Review.
Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis.
Clerico M, Artusi CA, Di Liberto A, Rolla S, Bardina V, Barbero P, De Mercanti SF, Durelli L. Clerico M, et al. Among authors: bardina v. Expert Opin Drug Saf. 2017 Aug;16(8):963-972. doi: 10.1080/14740338.2017.1346082. Epub 2017 Jul 5. Expert Opin Drug Saf. 2017. PMID: 28641055 Free article. Review.
Pregnancy Epigenetic Signature in T Helper 17 and T Regulatory Cells in Multiple Sclerosis.
Iannello A, Rolla S, Maglione A, Ferrero G, Bardina V, Inaudi I, De Mercanti S, Novelli F, D'Antuono L, Cardaropoli S, Todros T, Turrini MV, Cordioli C, Puorro G, Marsili A, Lanzillo R, Brescia Morra V, Cordero F, De Bortoli M, Durelli L, Visconti A, Cutrupi S, Clerico M. Iannello A, et al. Among authors: bardina v. Front Immunol. 2019 Jan 8;9:3075. doi: 10.3389/fimmu.2018.03075. eCollection 2018. Front Immunol. 2019. PMID: 30671056 Free PMC article.
Th22 cells are expanded in multiple sclerosis and are resistant to IFN-β.
Rolla S, Bardina V, De Mercanti S, Quaglino P, De Palma R, Gned D, Brusa D, Durelli L, Novelli F, Clerico M. Rolla S, et al. Among authors: bardina v. J Leukoc Biol. 2014 Dec;96(6):1155-64. doi: 10.1189/jlb.5A0813-463RR. Epub 2014 Aug 5. J Leukoc Biol. 2014. PMID: 25097195
Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months.
De Mercanti S, Rolla S, Cucci A, Bardina V, Cocco E, Vladic A, Soldo-Butkovic S, Habek M, Adamec I, Horakova D, Annovazzi P, Novelli F, Durelli L, Clerico M. De Mercanti S, et al. Among authors: bardina v. Neurol Neuroimmunol Neuroinflamm. 2016 Jan 21;3(1):e194. doi: 10.1212/NXI.0000000000000194. eCollection 2016 Feb. Neurol Neuroimmunol Neuroinflamm. 2016. PMID: 26819963 Free PMC article.
11 results